Hydrogel Spacer

FDA product code OVB · Class II (moderate risk) · 21 CFR 892.5725 · Radiology

The perirectal spacer is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of the perirectal spacer to reduce the radiation dose delivered to the anterior rectum. The perirectal spacer is composed of biodegradable material and maintains space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient’s body over time.

7510(k) clearances
0PMA approvals
2recalls

Manufacturers

510(k) clearances

510(k)DeviceApplicantDecision
K262151SpaceOAR Flex™ SystemOVB · Traditional Boston Scientific Corporation09/11/2026SE
K260119SpaceOAR Vue System (SV-2101)OVB · Special Boston Scientific Corporation02/10/2026SE
K222972BioProtect Balloon Implant™ SystemOVB · Traditional Bioprotect, Ltd.08/25/2023SE
K220641Barrigel Injectable GelOVB · Traditional Palette Life Sciences05/26/2022SE
K202224SpaceOAR SystemOVB · Special Boston Scientific Corporation08/28/2020SE
K182971SpaceOAR Vue HydrogelOVB · Traditional Augmenix, Inc.07/19/2019SE
K181465SpaceOAR SystemOVB · Special Augmenix, Inc.06/25/2018SE

Recalls

RecallProductFirmInitiated
Z-1003-2022 Class IISpaceOAR Vue System, UPN SV-1010 and SV-2101. Used to temporarily position the anterior…Users need to be aware that embolism is a possible adverse event associated with hydrogel misplacements.… Boston Scientific Corporation02/24/2022Open, Classified
Z-1002-2022 Class IISpaceOAR System, UPN SO-1010, SO-2101, SO-3101, and SO-4101. Used to temporarily…Users need to be aware that embolism is a possible adverse event associated with hydrogel misplacements.… Boston Scientific Corporation02/24/2022Open, Classified